European Journal of Biomedical and Pharmaceutical Sciences

VALPROIC ACID MONOTHERPAY AND ENDOCRINE ABNORMALITIES IN WOMEN WITH EPILEPSY

Fardin Faraji, Mohammad Reza Rezvanfar*, Afsoon Talaie-Zanjani and Afsaneh Morteza

ABSTRACT

Objective: Women with epilepsy have an increased risk of several endocrine disorders. Here we aim to study the prevalence of endocrine disorders, obesity, poly cystic ovarian syndrome and metabolic abnormalities in women on valproate monotherapy. Methods: It is a cross sectional study; to study the role of valproate sodium on metabolic measures of convulsive women. We obtained information of 40 patients who were exclusively using sodium valproate. We categorized the patients according to the number of risk factors. Results: The patients were stratified according to the number of risk factors, and the variables were compared between groups. There were 10 patients without any risk factor, 20 with one risk factor, and 10 with 2 or more factors for metabolic syndrome. When we compared the studied variables between groups, HDL and HOMA-IR were significantly different between groups, while there were not significant differences between other studied variables. While HDL was negatively correlated with LH in patients without any risk factor (r=-0.705, p<0.05) it was not correlated with it in patients with one risk factor (r=-0.017, p=0.94) and was positively correlated with it in patients with two or more risk factors (r=0.85, p<0.001). Conclusion: We showed the role of valporic acid monotherapy on the markers of metabolic syndrome and hormonal status of women with epilepsy. This is the first report reporting the correlation between LH and HDL in patients using sodium valproate monotherapy.

Keywords: Endocrine System Diseases; Epilepsy; Valproic Acid.